An increasingly global scientific capability supports Genzyme's commitment to create next-generation therapies and seek new indications to drive growth. Genzyme's Cambridge, U.K., research team is applying world-class antibody technology and expertise in the oncology, immune mediated disease and renal areas.

Declan Kelly / Senior Quality Director

•	INCREASING GLOBAL PRODUCTIVITY

Our Waterford, Ireland, facility's multi-product, global operations exemplify the leverage opportunities vertical integration affords. As Waterford provides finishing and packaging for a growing number of Genzyme therapies, people like Declan Kelly are key to managing quality, reducing costs and increasing efficiency.

Genzyme was the first U.S. biotechnology company to introduce therapeutic products in Japan without Japanese partners. Over the course of more than 20 years in Japan, Genzyme has built infrastructure and regulatory expertise-led by Shigetoyo Oguri-that have contributed to the rapid approval and launch of Aldurazyme, Myozyme and Elaprase there, all within one year.

Mary Yuska / Clinical Science Associate

•	LEVERAGING LSD BREADTH IN SALES

Genzyme goes to market through a relatively small, highly efficient sales force with expertise across multiple therapies-a source of leverage both in marketplace coverage and cost management. After 12 years at Genzyme, Mary Yuska represents all four Genzyme LSD products: Cerezyme, Fabrazyme, Aldurazyme and Myozyme.

Guided by knowledgeable local professionals like Sandeep Sahney and an emphasis on patient access, Genzyme is establishing a presence in India-and a number of other emerging markets-by collaborating with academic and government institutions, building infrastructure and providing Genzyme products and services that meet the region's needs.